Come January, Italy's CROS NT will have a new CEO, as Andrew MacGarvey will take the reins from longtime chief Paolo Morelli.
Global pharma giant Bayer has inked a three-year deal with the University of Texas' MD Anderson Cancer Center to run clinical trials, matching its investigators with patient-serving oncologists in a deep-seated collaboration.
AbbVie's PARP inhibitor veliparib improved outcomes for women with triple-negative breast cancer in a new investigator-sponsored study, charting a 52% complete response rate.
Aveo Oncology's long-troubled tivozanib is unlikely to meet its primary endpoint in a study on colorectal cancer, the company said, sending the biotech back to the drawing board after a high-profile failure in kidney cancer.
AstraZeneca's gout drug lesinurad hit its primary endpoint in a Phase III trial, the company said, a welcome turn for one of the drugmaker's top prospects amid a thin slate of late-stage therapies.
The vaccine, which is designed to work through early inhibition of amyloid beta depositions, is due to enter Phase I trials next year.
ImmunoCellular Therapeutics put out the word Wednesday afternoon that its dendritic cell-based vaccine for brain cancer flunked the key overall survival test in Phase II, news that swiftly wiped out more than half of the small biotech's market cap as shares instantly cratered.
Duke University leads the way among schools with on-campus CROs, and now Oxygen Biotherapeutics has entrusted the institution with handling late-stage studies of its promising heart drug.
Avanir Pharmaceuticals watched its shares tank more than 20% after its lead pain candidate failed to outdo a placebo in a Phase II study of patients with multiple sclerosis.
After months of building investors' expectations for its Phase IIb study for the cancer conjugate aldoxorubicin as a potential first-line treatment for soft tissue sarcoma, the small-cap biotech CytRx today said that it found an 80% to 100% improvement in the progression-free survival rate for its new-and-improved chemotherapy drug compared to the original chemo, sending its shares up more than 70% in premarket trading.